Evidence map›Paper›PMID 31847378›Full record

ArticleJournal of clinical medicine2019

Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.

Carl Fisher, Girgis Obaid, Carolyn Niu, Warren Foltz, Alyssa Goldstein, Tayyaba Hasan, Lothar Lilge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Carl FisherDepartment of Molecular Imaging, Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada.
Girgis ObaidWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-9452-4467
Carolyn NiuDepartment of Molecular Imaging, Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada.
Warren FoltzDepartment of Radiation Oncology, University Health Network, Toronto, ON M5G1L7, Canada.
Alyssa GoldsteinAnimal Resources Centre, University Health Network; Toronto, ON M5G1L7, Canada.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Lothar LilgeDepartment of Molecular Imaging, Princess Margaret Cancer Centre, Toronto, ON M5G1L7, Canada.
Harvard University · USPrincess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

Targeted Photoactivable Nanocells: Image-based Drug Delivery and Dosimetry in GBMR01CA156177 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA, POGUE, BRIAN WILLIAM · 2011 to 2015
$2.5M
Molecular imaging-directed bioengineering of nanoconjugates as adaptable tumor targeting platformsK99CA215301 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI OBAID, GIRGIS · 2018 to 2019
$358k
CIHR #97784NCI NIH HHS K99 CA215301NIH HHS K99CA215301NIH HHS R01CA156177Ontario Ministry of Health and Long-Term Care core grant to Princess Margaret Cancer Centre
6 · The paper itself

Abstract

backgroundMalignant gliomas are highly invasive and extremely difficult to treat tumours with poor prognosis and outcomes. Photodynamic therapy (PDT), mediated by Gleolan®, has been studied previously with partial success in treating these tumours and extending lifetime. We aim to determine whether combining PDT using ALA-protoporphyrin IX (PpIX) with a liposomal formulation of the clinical epidermal growth factor receptor (EGFR) inhibitor, lapatinib, would increase the anti-tumour PDT efficacy.

methodsLapatinib was given in vitro and in vivo 24 h prior to PDT and for 3-5 days following PDT to elicit whether the combination provided any benefits to PDT therapy. Live-cell imaging, in vitro PDT, and in vivo studies were performed to elucidate the effect lapatinib had on PDT for a variety of glioma cell lines and as well as GSC-30 neurospheres in vivo.

resultsPDT combined with lapatinib led to a significant increase in PpIX accumulation, and reductions in the LD

conclusionsAs lapatinib is approved for other oncological indications, a realization of its potential combination with PDT and in fluorescence-guided resection could be readily tested clinically. Furthermore, as its use would only be in acute settings, long-term resistance should not pose an issue as compared to its use as monotherapy.

Indexed as

ALA-PpIXcancergliomaMRIphotodynamic therapy

Identifiers

PMID31847378
PMCPMC6947404
OpenAlexW2996489767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.